Talk:Tofacitinib

Deletion of alopecia content seems excessive
[deletion of alopecia content] seems excessive if the content is supported by the sources ? Any objections or conditions to adding back ? - Rod57 (talk) 22:47, 30 January 2016 (UTC)

FDA approved for psoriatic arthritis
Tofacitinib for PsA: From Phase III to Approval - In mid-December, tofacitinib was approved for use in active psoriatic arthritis says FDA approved it for psoriatic arthritis in Dec 2017. - Rod57 (talk) 12:43, 29 December 2017 (UTC)

Still needs update?
Anyone know what the February 2017 update request was about, and whether it was fulfilled or not? Myoglobin (talk) 17:15, 24 January 2018 (UTC)
 * Not sure why this tag was added, but as tofacitinib is approved now, it should contain information about contraindications, interactions, pharmacokinetics, and probably a more extensive side effects section (see MOS:MED). Some long-term editors would also argue for removing information about (phase 2) studies. Also, the article seems to say that the drug isn't approved in the EU, which isn't true now . --ἀνυπόδητος (talk) 18:39, 24 January 2018 (UTC)